Brian Park

New York

Staff Editor for Experimentation and Personalization, Home at The New York Times

Articles

The gene expression signature of electrical stimulation in the human brain

Oct 22, 2024 | biorxiv.org | Snehajyoti Chatterjee |Yann Vanrobaeys |Annie Gleason |Brian Park

AbstractDirect electrical stimulation has been used for decades as a gold standard clinical tool to map cognitive function in neurosurgery patients1-8. However, the molecular impact of electrical stimulation in the human brain is unknown.
FDA Wants to See Diverse Participation in Clinical Trials

Jul 4, 2024 | neurologyadvisor.com | Brian Park

In an effort to improve clinical trial diversity, the Food and Drug Administration (FDA) has issued a new draft guidance for developing plans to enroll more participants from underrepresented racial and ethnic populations into clinical trials in the US.
FDA Approves Acetaminophen Injection in Multiple Doses

Jul 2, 2024 | clinicalpainadvisor.com | Brian Park

The Food and Drug Administration (FDA) has approved Acetaminophen Injection in multiple doses, manufactured by B. Braun Medical Inc. Acetaminophen Injection is indicated for the management of mild to moderate pain, and for moderate to severe pain with adjunctive opioid analgesics, in patients 2 years of age and older. It is also approved for the reduction of fever in adult and pediatric patients.
TempMonitor Helps Patients Monitor Temperature-Sensitive Medications

May 3, 2024 | thecardiologyadvisor.com | Brian Park

SpotSee has launched TempMonitor™, a single-use temperature indicator designed for patients who use insulin and glucagon-like peptide-1 (GLP-1) medications. Using SpotSee’s WarmMark® technology, TempMonitor is able to provide a visual indicator when a medication has been exposed to unacceptable temperature levels. These single-use indicators utilize a color-changing mechanism to alert users when the storage temperatures for the medications have exceeded 30°C (86°F).
TempMonitor Helps Patients Monitor Temperature-Sensitive Medications

Apr 24, 2024 | brnw.ch | Brian Park

SpotSee has launched TempMonitor™, a single-use temperature indicator designed for patients who use insulin and glucagon-like peptide-1 (GLP-1) medications. Using SpotSee’s WarmMark® technology, TempMonitor is able to provide a visual indicator when a medication has been exposed to unacceptable temperature levels. These single-use indicators utilize a color-changing mechanism to alert users when the storage temperatures for the medications have exceeded 30°C (86°F).
TempMonitor Helps Patients Monitor Temperature-Sensitive Medications

Apr 24, 2024 | renalandurologynews.com | Brian Park

SpotSee has launched TempMonitor™, a single-use temperature indicator designed for patients who use insulin and glucagon-like peptide-1 (GLP-1) medications. Using SpotSee’s WarmMark® technology, TempMonitor is able to provide a visual indicator when a medication has been exposed to unacceptable temperature levels. These single-use indicators utilize a color-changing mechanism to alert users when the storage temperatures for the medications have exceeded 30°C (86°F).
TempMonitor Helps Patients Monitor Temperature-Sensitive Medications

Apr 12, 2024 | endocrinologyadvisor.com | Brian Park

SpotSee has launched TempMonitor™, a single-use temperature indicator designed for patients who use insulin and glucagon-like peptide-1 (GLP-1) medications. Using SpotSee’s WarmMark® technology, TempMonitor is able to provide a visual indicator when a medication has been exposed to unacceptable temperature levels. These single-use indicators utilize a color-changing mechanism to alert users when the storage temperatures for the medications have exceeded 30°C (86°F).
Biologics Improve Outcomes in Severe Asthma, Regardless of Age

Mar 4, 2024 | pulmonologyadvisor.com | Brian Park

Among patients with severe asthma, treatment with biologics was associated with improved asthma outcomes across all age groups, according to results presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, held from February 23 to 26 in Washington, DC.
Biologics Compared for Moderate to Severe Uncontrolled Asthma and Nasal Polyps

Mar 4, 2024 | pulmonologyadvisor.com | Brian Park

Mepolizumab and tezepelumab were associated with the greatest reductions in asthma exacerbations among patients with moderate to severe, uncontrolled asthma with nasal polyps, when compared with placebo, according to results presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting, held from February 23 to 26 in Washington, DC.
One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanoma

Feb 26, 2024 | oncologynurseadvisor.com | Brian Park

The Food and Drug Administration (FDA) has granted accelerated approval to Amtagvi™ (lifileucel) for the treatment of adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Amtagvi is a tumor-derived autologous T-cell immunotherapy.